Page 57 - CIBEREHD2016-ENG

Most relevant scientific articles
• Garcia-Planella E., Manosa M., Cabre E., Marin L., Gordillo J., Zabana Y. et al. Fecal calprotectin levels are closely correlated with the absence of relevant mucosal lesions in postoperative Crohn’s Disease. Inflammatory Bowel Diseases. 2016;22(12):2879-2885.
• Julia A., Vinaixa M., Domenech E., Fernandez-Nebro A., Canete J.D., Ferrandiz C. et al. Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Medicine. 2016;14(1).
• Llao J., Naves J.E., Ruiz-Cerulla A., Gordillo J., Manosa M., Maisterra S. et al. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Digestive and Liver Disease. 2016;48(6):608-612.
• Marin-Jimenez I., Nos P., Domenech E., Riestra S., Gisbert J.P., Calvet X. et al. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology. 2016.
• Carpio D, Jauregui-Amezaga A, de Francisco R, de Castro L, Barreiro-de Acosta M, Mendoza JL et al. Tuberculosis in Anti-Tumor Necrosis Factor Treated Inflammatory Bowel Disease Patients after the Implementation of Preventive Measures: Compliance with Recommendations and Safety of Retreatment.Journal of Crohn’s & colitis. 2016.
Hightlights
In 2016, four FIS grants have been managed, and we have obtained an additional grant for a new project. In addition, we also participate in the intramural project of CIBEREHD, ACCES. IPs of our group lead the
FIS projects mentioned above, which are in accordance with the master plan, and 3 of them are clearly collaborative with other CIBEREHD groups. The main results of the scientific activity can be summarized as follows: i) Prediction of therapeutic response in steroid-treated moderate-to-severe ulcerative colitis (UC); ii) Identification of the mechanism of action linked to UC steroid-refractoriness; iii) Characterization of metabolic profiles in urine related to chronic inflammatory diseases; iv) Data compilation on natural history of postoperative Crohn’s disease (CD) under IMS prevention and design of new preventive strategies, as well as identification of new therapeutic targets; v) Description of the biological activity influenced by microorganisms in the CD; vi) Improvement in colonoscopy preparation for diabetic patients; vii) Characterization of variables associated to oesophageal motility disorders; and viii) Identification of patients with irritable bowel syndrome sensitive to therapeutic intervention on the intestinal microbiota. Some of these results have generated patents, such as the bioactive platform for wound healing of endoscopic lesions (EP163823365), or for drug release, as well as a panel of plasmatic biomarkers of corticosteroid failure in UC (last ones submitted). In the transfer activities, a collaboration agreement has been signed with Epithelion S.L. (Barcelona), and a study has been completed where we have transferred know-how to the industry (Lorén V, et al., 2016). Finally, the new edition of the international course “Miquel A. Gassull” on inflammatory bowel diseases (Badalona, 2016) is to be highlighted among the various formative activities.
EHD
research Groups 57